ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $221,000 | +15.7% | 9,500 | -17.4% | 0.03% | +3.7% |
Q3 2021 | $191,000 | -45.6% | 11,500 | -20.0% | 0.03% | -42.6% |
Q2 2021 | $351,000 | -79.6% | 14,377 | -78.5% | 0.05% | -80.2% |
Q1 2021 | $1,721,000 | +59.5% | 66,725 | +230.8% | 0.24% | +51.9% |
Q4 2020 | $1,079,000 | -39.8% | 20,170 | -53.6% | 0.16% | -44.3% |
Q3 2020 | $1,792,000 | +77.3% | 43,440 | +108.4% | 0.28% | +69.7% |
Q2 2020 | $1,011,000 | +6.6% | 20,844 | -7.1% | 0.16% | -4.6% |
Q1 2020 | $948,000 | +1.7% | 22,448 | +3.0% | 0.17% | +37.3% |
Q4 2019 | $932,000 | +16.2% | 21,785 | -2.3% | 0.13% | +9.6% |
Q3 2019 | $802,000 | -26.2% | 22,290 | -45.1% | 0.12% | -25.8% |
Q2 2019 | $1,086,000 | -47.3% | 40,637 | -47.1% | 0.16% | -44.6% |
Q1 2019 | $2,062,000 | -22.9% | 76,808 | -53.6% | 0.28% | -30.7% |
Q4 2018 | $2,674,000 | +98.1% | 165,366 | +154.4% | 0.40% | +122.0% |
Q3 2018 | $1,350,000 | +3.1% | 65,012 | +61.1% | 0.18% | +12.3% |
Q2 2016 | $1,310,000 | +55.0% | 40,344 | +33.5% | 0.16% | +45.9% |
Q1 2016 | $845,000 | – | 30,220 | – | 0.11% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |